Methods for treating an immune disorder-related disease by reducing autoreactivity in a T cell compartment

A pharmaceutical composition comprising:

• a sterile, enriched population of educated mononuclear cells (EMCs)
• wherein the population of EMCs comprises at least 1×10E8 cells;
• wherein the population of EMCs comprises a reduced population of TEM cells that express CD4+ and of TEM cells that express CD8+ as compared to an untreated control,
• wherein the population of EMCs comprises a population of TEM cells with upregulated expression of CCR7 as compared to an untreated control;
• wherein the pharmaceutical composition is produced by a method comprising:
• (1) isolating peripheral blood from a subject with a disorder with an autoimmune component;
• (2) isolating a population of T cells from the peripheral blood isolated from the subject;
• (3) co-culturing the isolated population of T cells with adherent umbilical cord mononuclear cells (UC-MNCs) in a bioreactor for at least 17 hours to produce the population of EMCs,
• wherein the adherent UC-MNCs comprise immature cells of hematopoietic lineage including lymphocytes, monocytes, stem cells (UC-SCs), progenitor cells, mesenchymal stromal cells, and factors derived from umbilical cord blood;
• wherein the UC-MNCs are at least 80% confluent;
• (4) collecting the population of EMCs;
• and
• (5) formulating the population of EMCs into the pharmaceutical composition.